


## Anterior Uveitis Therapeutics Drugs and Companies Pipeline Market H1 2016

WiseGuyReports.com adds "Anterior Uveitis - Pipeline Review, H1 2016" new report to its research database.

PUNE, INDIA, May 4, 2016 /EINPresswire.com/ -- The report "Anterior Uveitis - Pipeline Review, H1 2016" provides comprehensive information on the therapeutics under development for Anterior Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anterior Uveitis and features dormant and discontinued projects.

Complete Report Details Available at <a href="https://www.wiseguyreports.com/reports/anterior-uveitis-pipeline-review-h1-2016">https://www.wiseguyreports.com/reports/anterior-uveitis-pipeline-review-h1-2016</a>

This report features investigational drugs from across globe covering over 20 therapy areas and



The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Inquire more about this report at <a href="https://www.wiseguyreports.com/enquiry/anterior-uveitis-pipeline-review-h1-2016">https://www.wiseguyreports.com/enquiry/anterior-uveitis-pipeline-review-h1-2016</a>.

Anterior Uveitis - Companies Involved in Therapeutics Development: Aciont Inc. Aldeyra Therapeutics, Inc. Delenex Therapeutics AG EyeGate Pharmaceuticals, Inc.



Kineta, Inc. Neuroptis Biotech Virogenomics BioDevelopment, Inc.

## Featured News & Press Releases:

Mar 02, 2016: EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals for EGP-437

Jan 19, 2016: EyeGate Pharma Enrolls First Patient in Confirmatory Phase 3 Clinical Trial EGP-437-006 for Non-Infectious Anterior Uveitis

May 04, 2015: EyeGate Pharma Receives Positive Guidance From FDA on NDA Filing

Requirements of EGP-437 for the Treatment of Anterior Uveitis

Apr 16, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase II Clinical Trial

Mar 26, 2015: Aldeyra Therapeutics Opens Enrollment in Noninfectious Anterior Uveitis Phase II Clinical Trial

Mar 19, 2015: Kineta's ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases

Mar 02, 2015: Aldeyra Therapeutics Provides Update on NS2 Clinical Program

Feb 17, 2015: Kineta to Present New, Positive Data for ShK-186 in Autoimmune Eye Diseases and in ANCA Vasculitis at Upcoming Prestigious Science Conferences

Dec 18, 2014: Aldeyra Therapeutics Submits FDA IND Filing for Noninfectious Anterior Uveitis Apr 09, 2013: EyeGate Pharma's EGP-437 Matches Standard-of-care's Response Rate In Phase III Study In Patients With Anterior Uveitis

Get a sample copy at <a href="https://www.wiseguyreports.com/sample-request/anterior-uveitis-pipeline-review-h1-2016">https://www.wiseguyreports.com/sample-request/anterior-uveitis-pipeline-review-h1-2016</a>.

## Scope

- The report provides a snapshot of the global therapeutic landscape of Anterior Uveitis
- The report reviews pipeline therapeutics for Anterior Uveitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anterior Uveitis therapeutics and enlists all their major and minor projects
- The report assesses Anterior Uveitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anterior Uveitis

## Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anterior Uveitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anterior Uveitis pipeline

depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Order a Purchase Report Copy @ https://www.wiseguyreports.com/checkout?currency=one\_user-USD&report\_id=443171.

Norah Trent WiseGuy Research Consultants Pvt. Ltd. 16468459349 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.